New England Journal of Medicine· 2021Q1

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor, Johann S. de Bono, Kim N., Karim Fizazi et al.

2,658citations
Q1SCImago
2021year

Short summary

Adding lutetium-177–PSMA-617 (Lu-PSMA-617) to standard care significantly improved progression-free survival (PFS) and overall survival (OS) in patients with PSMA-positive metastatic castration-resistant prostate cancer.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Pulmonary and Respiratory Medicine

Pulmonary and Respiratory MedicineMedicine